Teva Pharmaceutical Industries Limited(TEVA) is having a Dividend Yield of 3.14% with the Annual cash Dividend per share of $1.16. The last quarter cash dividend per share pay out was $0.29. Teva Pharmaceutical Industries Limited has a 5 year average dividend yield of 2.14% and the stock has a Indicated annual dividend of $1.16. Teva Pharmaceutical Industries Limited(TEVA) formally announced its most recent dividend on November 17, 2016 with a Dividend per share of $0.29. The new indicated annual dividend based on announced dividend per share is $1.16. The dividend yield based on the forward looking indicated annual dividend is 3.14%. Teva Pharmaceutical Industries Limited(TEVA) has the most recent dividend payout ratio of 0.23 with a 5-year average payout ratio of 0.2. Companys change in pay out ratio when compared to the last 5 years average pay out ratio has been 0.03. The 5 year historical dividend growth of Teva Pharmaceutical Industries Limited(TEVA) is at the rate of 10.07% while the R-Squared dividend growth is 0.75. If the value of R-Square is close to one, it indicates a perfect fit and the higher value conforms to the regression line while data close to zero indicates the opposite.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) witnessed a decline in the market cap on Thursday as its shares dropped 2.61% or 0.96 points. After the session commenced at $36.4, the stock reached the higher end at $36.59 while it hit a low of $35.52. With the volume soaring to 14,532,756 shares, the last trade was called at $35.81. The company has a 52-week high of $59.345. The company has a market cap of $36,347 million and there are 1,015,000,000 shares in outstanding. The 52-week low of the share price is $31.9. Shares of Teva Pharmaceutical Industries Limited rose by 11.04% in the last five trading days and 5.01% for the last 4 weeks. Teva Pharmaceutical Industries Limited has dropped 3.89% during the last 3-month period . Year-to-Date the stock performance stands at -1.21%.
Currently the company Insiders own 7.1% of Teva Pharmaceutical Industries Limited shares according to the proxy statements. Institutional Investors own 55.03% of Teva Pharmaceutical Industries Limited shares. Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Teva Pharmaceutical Industries Ltd (ADR) was Reiterated by Maxim Group on Feb 13, 2017 to Hold, Lowers Price Target to $ 40 from a previous price target of $41 .Teva Pharmaceutical Industries Ltd (ADR) was Downgraded by Mizuho on Feb 10, 2017 to Neutral, Lowers Price Target to $ 27 from a previous price target of $40 .Teva Pharmaceutical Industries Ltd (ADR) was Upgraded by BofA/Merrill to Buy on Jan 31, 2017. Teva Pharmaceutical Industries Ltd (ADR) was Reiterated by Barclays on Jan 31, 2017 to Equal Weight, Lowers Price Target to $ 38 from a previous price target of $46 .Teva Pharmaceutical Industries Ltd (ADR) was Downgraded by JP Morgan to Neutral on Jan 20, 2017.
Teva Pharmaceutical Industries Ltd (ADR) Last issued its quarterly earnings results on Feb 13, 2017. The company reported $1.38 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $1.36. The company had revenue of $6492.00 million for the quarter, compared to analysts expectations of $6256.88 million. The companys revenue was up 33.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.32 EPS.
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.